Intracellular delivery of doxorubicin with RGD-modified sterically stabilized liposomes for an improved antitumor efficacy: In vitro and in vivo

Journal of Pharmaceutical Sciences

Volumn 94, Issue 8, 2005, Pages 1782-1793

  Xiong, Xiao Bing ^a   Huang, Yue ^b   Lu, Wan Liang ^a   Zhang, Xuan ^a   Zhang, Hua ^a   Nagai, Tsuneji ^c   Zhang, Qiang ^a  

^a PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^b INSTITUTE OF BASIC MEDICAL SCIENCES   (China)

^c HOSHI UNIVERSITY   (Japan)

Author keywords

Doxorubicin; RGD; Sterically stabilized liposomes; Targeted drug delivery; Tumor therapy

Indexed keywords

ARGINYLGLYCYLASPARTIC ACID; DOXORUBICIN; LIPOSOME;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CANCER INHIBITION; CIRCULATION TIME; CONFOCAL MICROSCOPY; CONTROLLED STUDY; CYTOTOXICITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG FORMULATION; DRUG TISSUE LEVEL; DRUG UPTAKE; ENDOCYTOSIS; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MELANOMA CELL; MOUSE; NONHUMAN; SPLEEN; TISSUE DISTRIBUTION;

EID: 25444471028     PISSN: 00223549     EISSN: None     Source Type: Journal    
DOI: 10.1002/jps.20397     Document Type: Article

References (38)

1. Ceh B, Winterhalter M, Frederik PM, Vallner JJ, Lasic DD. 1997. Stealth® liposomes: From theory to product. Adv Drug Deliv Rev 24:165-177.
2. Jain RK. 2001. Delivery of molecular medicine to solid tumors: Lessons from in vivo imaging of gene expression and function. J Control Release 74: 7-25.
3. Dvorak HF, Nagy JA, Dvorak JT, Dvorak AM. 1988. Identification and characterization of the blood vessels of solid tumors that is leaky to circulating macromolecules. Am J Pathol 133:95-109.
4. Yuan F, Leunig M, Huang SK, Berk DA, Papahadjopoulos D, Jain RK. 1994. Microvascular permeability and interstitial penetration of sterically stabilized (Stealth®) liposomes in a human tumor xenografts. Cancer Res 54:3352-3356.
5. Moreira JN, Gaspar R, Allen TM. 2001. Targeting Stealth liposomes in a murine model of human small cell lung cancer. Boichim Biophys Acta 1515:167-176.
6. Park JW, Kirpotin DB, Hong K, Shalaby R, Shao Y, Nielsen U, Marks JD, Papahadjopoulos D. 2000. Anti-HER2 immunoliposomes: Enhanced efficacy via intracellular delivery [abstract]. Proc Am Assoc Cancer Res 41:524.
7. Gabizon A, Shmeeda H, Horowitz AT, Zalipsky S. 2004. Tumor cell targeting of liposome-entrapped drugs with phospholipid-anchored folic acid-PEG conjugates. Adv Drug Deliv Rev 56:1177-1192.
8. Sapra P, Allen TM. 2002. Internalizing antibodies are necessary for improved therapeutic efficacy of antibody-targeted liposomal drugs. Cancer Res 62: 7190-7194.
9. Ruoslahti E. 1996. RGD and other recognition sequences for integrins. Annu Rev Cell Dev Biol 12:697-715.
10. Zitzmann S, Ehemann V, Schwab M. 2002. Arginine-glycine-aspartic acid (RGD)-peptide binds to both tumor and tumor-endothelial cells in vivo. Cancer Res 62:5139-5143.
11. Hart SL, Knight AM, Harbottle RP, Mistry A, Hunger HD, Cutler DF, Williamson R, Coutelle C. 1994. Cell binding and internalization by filamentous phage displaying a cyclic Arg-Gly-Asp-containing peptide. J Biol Chem 269:12468-12474.
12. Pasqualini R, Koivunen E, Ruoslahti E. 1997. Alpha v integrins as receptor for tumor targeting by circulating ligands. Nat Biotechnol 15:542-546.
13. Pijuan-Thompson V, Gladson CL. 1997. Ligation of integrin α5β1 is required for internalization of vitronectin by integrin αvβ3. J Biol Chem 272: 2736-2743.
14. Triantafilou K, Takada Y, Triantafilou M. 2001. Mechanisms of integrin-mediated virus attachment and internalization process. Crit Rev Immunol 21: 311-322.
15. Isberg RR, Tran Van Nhieu G. 1994. Binding and internalization of microorganisms by integrin receptors. Trends Microbiol 2:10-14.
16. Aoki Y, Hosaka S, Kawa S, Kiyosawa K. 2001. Potential tumor-targeting peptide vector of histidylated oligolysine conjugated to a tumor-homing RGD motif. Cancer Gene Ther 8:783-787.
17. Hosseinkhani H, Tabata Y. 2004. PEGylation enhances tumor targeting of plasmid DNA by an artificial cationized protein with repeated RGD sequences, Pronectin. J Control Release 97:157-171.
18. Harvie P, Dutzar B, Galbraith T, Cudmore S, O'Mahony D, Anklesaria P, Paul R. 2003. Targeting of lipid-protamine-DNA (LPD) lipopolyplexes using RGD motifs. J Liposome Res 13:231-247.
19. Hood JD, Bednarski M, Frausto R, Guccione S, Reisfeld RA, Xiang R, Cheresh DA. 2002. Tumor regression by targeted gene delivery to the neovasculature. Science 296:2404-2407.
20. Kunath K, Merdan T, Hegener O, Häberlein H, Kissel T. 2003. Integrin targeting using RGD-PEI conjugates for in vitro gene transfer. J Gene Med 5:588-599.
21. Haran G, Cohen R, Bar LK, Barenholz Y. 1993. Transmembrane ammonium sulfate gradient in liposomes produce efficient and stable entrapment of amphipathic weak bases. Biochim Biophys Acta 1151:201-215.
22. Mosmann T. 1983. Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. J Immunol Methods 65:55-63.
23. Shinozawa S, Mimaki Y, Araki Y, Oda T. 1980. Determination of the concentration of adriamycin and its metabolites in the serum and tissues of ehrlich carcinoma-bearing mice by high-performance liquid chromatography. J Chromatogr 196: 463-469.
24. Hu YP, Henry-Toulme N, Robert J. 1995. Failure of liposomal encapsulation of doxorubicin to circumvent multidrug resistance in an in vitro model of rat glioblastoma cells. Eur J Cancer 31:389-394.
25. Düzgünes N, Nir S. 1999. Mechanisms and kinetics of liposome-cell interactions. Adv Drug Deliv Rev 40:3-18.
26. Vertut-Doi A, Ishiwata H, Miyajima K. 1996. Binding and uptake of liposomes containing a poly (ethylene glycol) derivative of cholesterol (Stealth® liposomes) by the macrophage cell line J774: Influence of PEG content and its molecular weight. Biochim Biophys Acta 1278:19-28.
27. Park JW, Kirpotin DB, Hong K, Shalaby R, Shao Y, Nielsen UB, Marks JD, Papahadjopoulos D, Benz CC. 2001. Tumor targeting using anti-her2 immunoliposomes. J Control Release 74:95-113.
28. Panetti TS, Mckeown-Longo PJ. 1993. The áíâä integrin receptor regulates receptor-mediated endocytosis of vitronectin. J Biol Chem 268:11492-11495.
29. Matsumoto T, Numata M, Anada T, Mizu M, Koumoto K, Sakurai K, Nagasaki T, Shinkai S. 2004. Chemically modified polysaccharide schizophyllan for antisense oligonucleotides delivery to enhance the cellular uptake efficiency. Biochim Biophys Acta 1670:91-104.
30. Lee RJ, Low P. 1995. Folate-mediated tumor cell targeting of liposome-entrapped doxorubicin in vitro. Biochim Biophys Acta 1233:134-144.
31. Schiffelers RM, Koning GA, tens Hagen LM, Fens MH, Schraa AJ, Janssen AP, Kok RJ, Molema G, Storm G. 2003. Anti-tumor efficacy of tumor vasculature-targeted liposomal doxorubicin. J Control Release 91:115-122.
32. Schraa AJ, Kok RJ, Moorlag HE, Bos EJ, Proost JH, Meijer DK, de Leij LF, Molema G. 2002. Targeting of RGD-modified proteins to tumor vasculature: A pharmacokinetic and cellular distribution study. Int J Cancer 102:469-475.
33. Savill J, Dransfield I, Hogg N, Haslett C. 1990. Vitronectin receptor-mediated phagocytosis of cells undergoing apoptosis. Nature 343:170-173.
34. Iinuma H, Maruyama K, Okinaga K, Sasaki K, Sekine T, Ishida O, Ogiwara N, Johkura K, Yonemura Y. 2002. Intracellular targeting therapy of cisplatin-encapsulated transferrin-polyethylene glycol liposomes on peritoneal dissemination of gastric cancer. Int J Cancer 99:130-137.
35. Turk MJ, Waters DJ, Low PS. 2004. Folate-conjugated liposomes preferentially target macrophages associated with ovarian carcinoma. Cancer Letters 213:165-172.
36. Emanuel N, Kedar E, Bolotin E, Smorodinsky NI, Barenholz Y. 1996. Targeted delivery of doxorubicin via sterically stabilized immunoliposomes: Pharmacokinetics and biodistribution in tumor-bearing mice. Pharm Res 13:861-868.
37. Unezaki S, Maruyama K, Hosoda J, Nagae I, Koyanagi Y, Nakata M. 1996. Direct measurement of the extravasation of polyethyleneglycol-coated liposomes into solid tumor tissue by in vivo fluorescence microscopy. Int J Pharm 144:11-17.
38. Uster PS, Working PK, Vaage J. 1998. Pegylated liposomal doxorubicin (DOXIL®, CAELYX®) distribution in tumor models observed with confocal laser scanning microscopy. Int J Pharm 162:77-86.